Neuroendocrine

Thorvardur Halfdanarson, M.D., Medical Oncologist, Department of Oncology, Mayo Clinic: What I think Mayo has to offer is really being a full service station, if you will, for all things pancreatic. Where there's really a team approach…

Pamela L. Kunz, MD, Associate Professor of Medicine (Oncology); Yale School of Medicine MONDAY, June 19, 2023 (HealthDay News) -- Pancreatic cancer is often considered a death sentence,…

New York, USA, May 29, 2023 (GLOBE NEWSWIRE) -- Propulsion of Neuroendocrine Tumors Pipeline as Novel and Extensive 60+ Therapies Likely to Enter in the Treatment Domain | DelveInsight  The prevalence of Neuroendocrine Tumors has been…

THURSDAY, Feb. 23, 2023 (HealthDay News) -- For patients with primary lung neuroendocrine tumor (LNET), stereotactic body radiotherapy (SBRT) is well tolerated and provides excellent locoregional control, according to a study published…

Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECsPart of a broad collaboration with The Cancer Epigenetics Institute (CEI) MADRID, Spain and…

Elana Gotkine FRIDAY, Dec. 30, 2022 (HealthDay News) -- Independence is valued over survival among adult patients with neuroendocrine tumors (NETs), according to a study published in the December issue…

A novel PET radiotracer can accurately assess the presence of a biomarker that indicates the level of tumor aggressiveness in neuroendocrine neoplasms (NENs). According to research published in the September issue of The Journal of Nuclear…

Combination therapy of GP-2250 and gemcitabine proved to be effective for the treatment of pancreatic neuroendocrine tumors in vitro and in vivo, without the development of secondary resistances Data bolsters rationale for further…

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 02, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) announced that the U.S. Food and Drug Administration (“FDA” or the…

DURHAM, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today…